• Technology
  • Applications
    • AML MRD
    • Mutagenesis
    • Cellular Immunotherapy
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
    • Investors
  • Contact
TwinStrand Biosciences
  • Technology
  • Applications
    • AML MRD
    • Mutagenesis
    • Cellular Immunotherapy
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
    • Investors
  • Contact

 

Patents

 

This page is intended to serve as notice under 35 U.S.C. § 287(a) that TwinStrand products and services, including but not limited to TwinStrand Duplex Sequencing™ Kits, the TwinStrand DuplexSeq™ Bioinformatics Platform, and/or methods of using the foregoing, may be covered by one or more of the following U.S. patent(s), which are owned by or exclusively licensed to TwinStrand Biosciences, Inc. (“TwinStrand”):

Patent No.

Title of Patent

Country

Download

9,752,188

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

10,287,631

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

10,570,451

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

10,385,393

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

10,370,713

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

10,604,804

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

10,689,699

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

10,689,700

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

10,711,304

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

10,752,951

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

10,760,127

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

11,047,006

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

United States

2828218

Methods of Lowering the Error Rate of Massively Parallel DNA Sequencing using Duplex Consensus Sequencing

Europe

2,872,141

Methods for Accurate Sequencing of DNA

Canada

2855707

Methods for Accurate Sequencing of DNA

Europe

2013267609

Methods for Accurate Sequencing of DNA

Australia

9,970,054

Methods for Accurate Sequencing of DNA

United States

10,870,882

Methods for Accurate Sequencing of DNA

United States

Additional patents pending in the U.S. and in several foreign jurisdictions.

 

 

TwinStrand Biosciences, Inc.
3131 Elliott Ave, Suite 750 • Seattle, WA 98121 • USA
+1 (877) 202-TWIN

 

For Research Use Only. Not for use in diagnostic procedures.

©2022 TwinStrand Biosciences, Inc. All rights reserved. All trademarks are the property of TwinStrand Biosciences, Inc. or their respective owners.  Legal Notices

  

American Society of Hematology (ASH)

December 5-8, 2020 – Virtual

 

Poster Presentation

 

“Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia”

 

Presented by Jake Higgins, Senior Scientist – December 6, 2020 7:00 a.m.-3:30 p.m. PST

 

Conference Website

 

Society of Toxicology (SOT)

March 10-14, 2019 – Baltimore, MD

 

Poster Presentations

 

 

View Poster

 

 

Conference Website

 

AACR Annual Meeting – San Diego, CA

March 29-April 3, 2019

 

Poster Presentations

 

 

View Poster

 

 

View Poster

Presentations by CEO Jesse Salk, MD, PhD – AGBT 2020

Ultra-Sensitive Residual Leukemia Detection with Patient-Specific Dupex Sequencing